Match!
Hertzel C. Gerstein
Population Health Research Institute
EndocrinologyCardiologyType 2 diabetesDiabetes mellitusMedicine
505Publications
93H-index
53.9kCitations
What is this?
Publications 491
Newest
Source
#1Abhinav Sharma (Stanford University)H-Index: 12
#2Neha J. Pagidipati (Duke University)H-Index: 11
Last. Rury R. Holman (University of Oxford)H-Index: 99
view all 21 authors...
Responding to concerns about the potential for increased risk of adverse cardiovascular (CV) outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, the U....
Source
#1Abhinav SharmaH-Index: 12
#2Neha J. PagidipatiH-Index: 11
Last. Rury R. HolmanH-Index: 99
view all 21 authors...
Responding to concerns about the potential for increased risk of adverse cardiovascular outcomes, specifically myocardial infarction, associated with certain glucose-lowering therapies, the US Food...
Abstract Objective Diet-related quality of life has not been explored previously in patients with type 2 diabetes using sodium glucose cotransporter 2 (SGLT-2) inhibitors, the latest class of diabetes medications. In this study, we sought to describe the patient experience on SGLT-2 inhibitors and examine whether there have been improvements in dietary perception and satisfaction with these drugs. Methods Adults ≥40 years of age with type 2 diabetes and using SGLT-2 inhibitors for at least 1 mon...
Source
#1William WhiteleyH-Index: 30
#2Sonia S. AnandH-Index: 76
Last. Salim YusufH-Index: 213
view all 18 authors...
Source
#1Hertzel C. Gerstein (HHS: Hamilton Health Sciences)H-Index: 93
Source
#1Jennifer SjaardaH-Index: 3
#2Hertzel C. Gerstein (McMaster University)H-Index: 93
Last. Guillaume ParéH-Index: 52
view all 7 authors...
Disease risk varies significantly between ethnic groups, however, the clinical significance and implications of these observations are poorly understood. Investigating ethnic differences within the human proteome may shed light on the impact of ancestry on disease risk. We used admixture mapping to explore the impact of genetic ancestry on 237 cardiometabolic biomarkers in 2,216 Latin Americans within the Outcomes Reduction with an Initial Glargine Intervention (ORIGIN) study. We developed a var...
Source
#1Marie Pigeyre (McMaster University)H-Index: 17
#2Jennifer Sjaarda (McMaster University)H-Index: 3
Last. Guillaume ParéH-Index: 52
view all 8 authors...
OBJECTIVE To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN; NCT00069784) trial, and their effects on type 2 diabetes risk were estimated from 18 studies of the DIAbetes Genetics Replication And Meta-analys...
Source
#1Mohammed A. M. Farooqi (McMaster University)H-Index: 1
#2Hertzel C. Gerstein (McMaster University)H-Index: 93
Last. Darryl P. Leong (McMaster University)H-Index: 33
view all 4 authors...
Background Frailty is associated with higher mortality in individuals at high cardiovascular disease (CVD) risk. We hypothesize that frailty is a more important prognostic factor than CVD risk fact...
Source
#1Mario Luca Morieri (Harvard University)H-Index: 7
#2Hetal Shah (Harvard University)H-Index: 6
Last. Assunta PandolfiH-Index: 26
view all 27 authors...
The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-alpha), could be used to improve the selection of patients with type 2 diabetes who may derive cardiovascular benefit from addition of this treatment to statins. We identified a common variant at the PPARA locus (rs6008845, C/T) displaying a stud...
Source
12345678910